FLGT News and Press, Fulgent Genetics Inc. From 11/09/21

Fulgent Genetics (NASDAQ:FLGT): Q3 Non-GAAP EPS of $4.05 beats by $0.80; GAAP EPS of $3.93 beats by $2.36. Revenue of $227.87M (+124.0% Y/Y) beats by $20.82M. Press Release Q4 2021 Outlook: Total Revenue of approximately $189 million, Core Revenue of approximately $32 million, representing gr...

Revenue grows 124% year-over-year to $227.9 million Core Revenue grows 292% year-over-year to $40.1 million Raises Full Year Revenue guidance to $930 million from $800 million, given recent strength in core and COVID-19 business Fulgent Genetics, Inc. (NASDAQ: FLGT) ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of it...

Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiver™ for Early Liver Cancer Detection Data from the ENCORE study to be presented at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Disease...

Helio Health and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021 PR Newswire IRVINE , Calif. and TEMPLE CITY, Calif. , Nov. 1, 2021 /PRNewswire/ -- Helio Health ("Helio"), an AI-dri...

Old West manages long only and long/short investment strategies based upon the companies that we uncover through our simple yet sound investment process. The third quarter of 2021 ended with the market searching for direction. The S&P 500 fell 4.6% in September but was still just ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has launched an ant...

The genomic revolution is upon us, but you wouldn't know it just by looking at the share prices of these three stocks. Shares of Fulgent Genetics (NASDAQ: FLGT) , Amyris (NASDAQ: AMRS) , and Pacific Biosciences of California (NASDAQ: PACB) have been absolutely h...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...

Most investors will tell you they love to buy stocks when they are cheap. But that typically means taking on some uncertainty. After all, Wall Street doesn't sell a stock unless it believes there is a better place for the money -- at least in the short term. That's why long-term investi...